CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy
DR220214
Phase 2 other active
Quick answer
CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy for Pneumocystis pneumonia is a Phase 2 program (other) at Tour Hekla with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tour Hekla
- Indication
- Pneumocystis pneumonia
- Phase
- Phase 2
- Modality
- other
- Status
- active